论文部分内容阅读
Background: Deregulation of the hepatocyte growth factor(HGF)/MET pathway has been implicated in gastric cancer(GC),representing a potential target in gastric or gastroesophageal junction(G/GEJ)cancer.However,the anti-tumor effect of anti-MET therapy is still controversial.Methods: We evaluated the expression and amplification of MET in Chinese patients with advanced G/GEJ cancer using different cut-off values and explored the anti-tumor efficacy of a highly selective MET kinase inhibitor,AMG 337,in a panel of 12 GC cell lines.